NeuroSense Therapeutics will consolidate every 20 ordinary shares into one, reducing issued and outstanding shares from 37,938,036 to 1,896,902, subject to fractional-share adjustments. Investors will see post-split trading begin on Nasdaq Capital Market on September 14, while outstanding warrants and Options receive proportional exercise-price and share-count adjustments.

Key Highlights

  • Nasdaq Capital Market trading for the post-split ordinary shares will begin Monday, September 14, 2026.
  • NeuroSense Therapeutics’ authorized Share Capital will remain unchanged after the consolidation.
  • The new CUSIP for the ordinary shares will be M74240207.

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) will consolidate every 20 ordinary shares into one under a 1-for-20 reverse split. The transaction will reduce issued and outstanding ordinary shares from 37,938,036 to 1,896,902, subject to any further adjustment arising from fractional-share treatment.

Fractional Shares and Instrument Adjustments

Fractional ordinary shares will not be issued as part of the consolidation. Outstanding warrants and options will receive proportional adjustments to both their per-share exercise prices and the number of ordinary shares issuable upon exercise. The new CUSIP assigned to the ordinary shares is M74240207.

September 14 Nasdaq Trading Date

Trading in the post-split ordinary shares on the Nasdaq Capital Market will begin Monday, September 14, 2026. Authorized share capital will remain unchanged. The stated trading date is the first date after implementation of the reverse split.